Xuan-Yi Wang

Professor Wang received medical training at Anhui Medical University, and a Ph.D. on epidemiology from School of Public Health, followed by a postdoctoral training on immunology and molecular virology at Shanghai Medical College, Fudan University. 

He is a senior scientist with an extensive experience in infectious disease research and vaccinology. He combines academic knowledge of epidemiology with the crucial understanding of healthcare systems and infrastructure in remote areas of China. The focus of his early work was hepatitis. With colleagues from Fudan University he conducted several landmark studies on hepatitis A control. He joined the International Vaccine Institute (IVI) in 2003 with a focus on the enteric infectious disease research, including rotavirus, Shigella, S.typhi, S.paratyphi, and cholera. IVI provided opportunities to interact with a large multidisciplinary team which including social scientists and statisticians from Southeast Asia, Africa, Europe, and USA. After leaving IVI in 2007, he continued to work on viral hepatitis and enteric infectious diseases with an emphasis on epidemiology and vaccinology. Currently, His team works on the R&D of rotavirus and norovirus vaccines, and is responsible for the clinical development of a therapeutic hepatitis B vaccine. He has involved in the clinical development of vaccines and immunization strategy against hepatitis A, B and E, rotavirus, EV71 in China, and has published over 130 papers on vaccines and infectious diseases in peer-reviewed journals. 

He serves as external expert of the Center for Drug Evaluation, National Medical Products Administration, and member of the National Immunization Advisory Committee in China. More recently he serves as a member of DSMBs and is overseeing clinical trials of several COVID-19 vaccines developed in China.